Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

BACKGROUND: An open-label, non-comparative study assessed the efficacy and safety of nivolumab in Japanese patients with first recurrence glioblastoma. METHODS: Patients with first recurrence of histologically confirmed World Health Organization Grade IV glioma, after treatment with temozolomide and...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580927/
https://www.ncbi.nlm.nih.gov/pubmed/34586548
http://dx.doi.org/10.1007/s10147-021-02028-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580927/
https://www.ncbi.nlm.nih.gov/pubmed/34586548
http://dx.doi.org/10.1007/s10147-021-02028-1

Ejemplares similares